PharmaMedDevice - March 26-28, 2008 - Pennsylvania Convention Center, Philadelphia, PA PharmaMedDevice - March 26-28, 2008 - Pennsylvania Convention Center, Philadelphia, PA PharmaMedDevice - March 26-28, 2008 - Pennsylvania Convention Center, Philadelphia, PA

Print Friendly Pages Print-Friendly Pages

Industry Statistics

PharmaMedDevice's bulletin is intended to serve as a indicator of recent trends in the medical device, pharmaceutical, and biologic industries. Please review the industry statistics and facts below.


Biotechnology Statistics

Combination Products Statistics

Drug Delivery Statistics

General Healthcare Statistics

Medical Device Statistics

Nanotechnology Statistics

Pharmaceutical Statistics



  • Orthobiologics was a $2B market in 2006 and is expanding at a compounded annual growth rate of 13%.  Among the products most likely to spur this growth are cytokines, bone morphogenetic proteins and tissue engineering products.  Source:  Millennium Research Group
  • San Francisco, New England, San Diego, and New Jersey are top in the life science industry's growth based on the number of biotech companies around the country. Source: Palm Beach Post, The, May 9, 2007
  • Philadelphia is an example of a region that excels in a combination of the bioscience subsectors. Source: Bioscience 07: Growing the Nation’s Bioscience Sector, Battelle, 2007
  • Philadelphia has one of the strongest biotech clusters in the United States — 80 percent of the world's pharmaceutical companies have a presence in the region and the biotech startups are booming there.”  Source: Area Development Online, June 2005
  • Biotechnology companies spent an average of eight years and $1.2 billion to get a new treatment to the market, about 24 percent more than it cost makers of traditional drugs to develop a medicine. Source: Tufts Center for the Study of Drug Development at Tufts University
  • The American biotechnology industry has surpassed pharmaceutical companies for the third straight year as the primary source of new medicines, and biotech revenue jumped nearly 16 percent to a record $50.7 billion in 2005.  Source: Ernst & Young LLP, 2006
  • The biocompatible materials market is estimated to reach nearly $11.9 billion by 2008.1 Biomaterials are used in every medical device meant for body contact, from orthopedic implants and bone grafts to coronary stents and soluble sutures.  Source: Biocompatible Materials for the Human Body, 2003
  • The biotech industry has mushroomed since 1992, with U.S. health-care biotech revenues increasing from $8 billion in 1992 to $39 billion in 2003.  Source: Biotechnology Industry Organization (BIO,) 2006
  • Market capitalization, the total value of publicly traded biotech companies (U.S.) at market prices, was $311 billion as of early April 2005.  Source: Biotechnology Industry Organization (BIO,) 2006
  • Biotechnology is one of the most research-intensive industries in the world. The U.S. biotech industry spent $17.9 billion on research and development in 2003.  Source: Biotechnology Industry Organization (BIO,) 2006

    Back to top

Combination Products

  • “…an estimated 30% of new products under development are “combo products” – involving medical devices embedded with pharmaceutical or biologics components.  But for manufacturers, along with these exciting new opportunities, the convergence of drugs/biologics and devices also brings a host of regulatory challenges.” Source:  Combination Products- Navigating Two FDA Quality Systems,  Microtest White Paper, 2007
  • The combination products market is estimated at $5.9B in 2004, and will continue to grow at a compound annual rate of 10% through 2009. By 2009, the market is expected to reach approximately $9.5B worldwide with a majority of these revenues from drug-eluting stents and steroid-eluting electrodes. Source: Navigant Consulting, Inc.
  • “Combination products have the regulatory flexibility to apply the most appropriate regulation to a combination product by tailoring the approach to taking pieces of drug regulation, pieces of device regulation, or biologics, as appropriate.” Source: Mark Kramer, Former Director of the FDA’s Office of Combination Products, September 2006
  • In 2004, the US held approximately 65% of the drug-device combination product market. By 2010, the US is projected to hold 57%.  Source: Business Communications Inc.
  • “RAPS’ research shows steady growth in the number of regulatory professionals involved in combination products – from an estimated 12% in 1999 to nearly 30% today.”  Source: Sherry Keramidas, PhD, RAPS Executive Director, September 2006
  • Cardiovascular related combination product revenues will account for approximately 88% of worldwide sales in 2009. A majority of these revenues will be due to drug-eluting stent sales while steroid eluting electrode and waterjet device revenues account for the remainder.  Source: Front Line Strategic Consulting, Inc.

    Back to top

Drug Delivery

  • The implantable/injectable drug delivery market generated record revenues of $9.8bn (€7.4bn) worldwide in 2006 but is set to continue growing, driven by growing demand for novel drug delivery technologies. Source: Drug Delivery Markets, 2nd Edition, Vol II: Implantable / Injectable Delivery Systems Report 2007, Kalorama Information
  • The US drug delivery market value might reach nearly $85 billion by 2010. Source: Takeda Pacific, Drug Delivery Systems Report September 2006
  • The global market for drug-device combinations is expected to increase at an average annual growth rate of 13.6% and reach $11.5B in 2010, compared with $5.4B in 2004.  Source:  Business Communications Co. Inc.
  • The US pharmaceutical packaging market is set to grow at a compound annual rate of 3.3% between 2004 and 2011. A major portion (16.8%) of this revenue is set to come from the fastest growing prefilled syringes sector. Source: Frost & Sullivan, US Pharmaceutical Packaging Market Report 2005
  • The US advanced drug delivery market is tipped to grow more than 18% and exceed $76B by 2014.  However, only a handful of contract manufacturing organizations exist that can fulfill the task of making such specialized devices on a large scale.  Source: in-Pharma 2006
  • The 2005 market size for nanotechnology drug delivery systems alone was estimated at $980 million and expected to group 54% annually over the next five years. Source: The Nanotech Report 4th Edition, Lux Research, 2006
  • Osteoporosis is expected to have the largest revenue gain in the intranasal drug delivery market, increasing to 18.2% of the market by 2012. Source: Frost & Sullivan Healthcare Group, March 2006

    Back to top

General Healthcare

  • 125 million Americans have 1 or more chronic conditions (e.g. congestive heart failure, diabetes.) Chronic diseases account for 75% of all health care expenditures.  Source: Burrill & Company, 2006

    Back to top

Medical Device

  • The Philadelphia metro area ranked number three as a metropolitan area with the largest total employment levels in the biosciences (medical device & equipment, drugs & pharmaceutical, research, testing & medical laboratories, and agricultural, feedstock & chemicals.) Source: Bioscience 07: Growing the Nation’s Bioscience Sector, Prepared by Battelle, January 2007.
  • Philadelphia ranked in the top 10 metropolitan areas with largest employment in medical devices and equipment.  Philadelphia is an example of a region that is not niched in one speciality, but excels in a combination of the bioscience subsectors. Source: Bioscience 07: Growing the Nation’s Bioscience Sector, Prepared by Battelle, January 2007.
  • The medical device market in the United States should be approximately $86 billion by the end of 2006 (close to $220 billion worldwide), with a 10% annual growth rate expected for the coming year. Source: AdvaMed 2006
  • The market for coatings and surface-treatment processes used on medical devices will reach more than $5.31 billion by 2010. The 12.4% annual growth rate will be fueled by explosive growth in high-value combination products. Source:  Medical Device Coatings Report, BCC Research, April 2006
  • During period of 2001-1006, California companies - $23.9 billion of increased market value creation, followed by Indiana at $22.9 billion, and Massachusetts at $20.7 billion. Source: Medical Device Industry Market Capitalization Report, 2001–2006
  • The medical devices and equipment industry employs more than 411,400 workers, accounting for nearly one third of all US bioscience jobs.  Source: Medical Product Outsourcing 2006
  • Pennsylvania and New York included in Top 5 US states for Medical Device Employment - The thriving medical device industry in Massachusetts is the East Coast equivalent of the San Francisco Bay Area.  Source: US Bureau of Labor Statistics, 2005
  • The spinal devices segment (of the marketplace), with a striking growth rate of 20 to 25 percent annually, leads the orthopedic market.  Extensive research on bone growth factors and fusion biologics has been integral to emerging technologies for the spine market. Source:  Frost & Sullivan’s Emerging Technologies for the Spine Market (Technical Insights), published September 2006
  • The medical device industry in Canada has approximately $5 billion in sales, with 50% of those sales in Ontario and 25% occurring in Quebec. Source:, 2007

    Back to top


  • The demand for nanotechnology medical products will grow by more than 17 percent annually to reach $53 billion in 2011. Source: The Freedonia Group, Nanotechnology in Health Care to 2011 Report, February, 2007  
  • The Freedonia Group projects that nanotechnology will account for drug delivery and biomedical product demand of $3.7 billion in 2009, up from $165 million in 2004. The largest share of opportunities will emerge in pharmaceutical applications, which are expected to reach $3.1billion in 2009 and expand to $18 billion in 2014.  Source: The Freedonia Group
  • With at least 12 nanomedicines already approved and progressively more in active development, the next five years should see a steady succession of new nanotech-based drugs, imaging agents, and diagnostic products entering the marketplace. The most active areas of medical nanotechnology are in drug delivery and in vivo imaging.  Source: AdvanceTech Monitor, 2006
  • As of mid-2006, 130 nanotech-based drugs and delivery systems and 125 devices or diagnostic tests are in preclinical, clinical or commercial development. The combined market for nanoenabled medicine (drug delivery, therapeutics and diagnostics) will jump from just over $1 billion in 2005 to almost $10 billion in 2010 and the US National Science Foundation predicts that nanotechnology will produce half of the pharmaceutical industry product line by 2015. Source: The Nanotech Report 4th Edition, Lux Research, 2006
  • The total amount budgeted for research and development by federal agencies for the National Nanotechnology Initiative are as follows:
    2005 = $34.8 million, 2006 = $37.5 million, and 2007 = $44.1 million dollars. Source: Dr. Celia Merzbacher, U.S. Office of Science and Technology Policy

    Back to top


  • The USA is the world's largest and wealthiest pharmaceutical market, accounting for around 48% of the world total. Per capita expenditure on drugs is US $1,069 in 2006, nearly double the level found in the rest of the world.  Source: Espicom Business Intelligence, 2006
  • Big Pharma companies forecast about 60% of revenue growth to come from biologic products. The forecast revenue growth rate to 2010 for biologics is 13%, compared to 0.9% for small molecule products.  Source: Datamonitor
  • The US market for pharmaceutical packaging will grow by nearly a third between 2004 and 2011, from $2.6 billion to just under $3.4 billion. At the same time, pharmaceutical packaging will play an increasingly important role in effective drug delivery.  Source: Frost & Sullivan
  • 13 products were added to the list of blockbuster medications, bringing the number of medications exceeded the $$1 billion dollar annual sales mark to 94.  Source: Pharmaceutical Executive

    Back to top
  PharmamMedDevice Blog

 Download PharmaMedDevice Podcasts
Managed and Produced by:
Reed Life Sciences